Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,616 GBX | +1.46% | +3.14% | +0.95% |
Apr. 02 | RBC Lifts Diploma PT, Maintains Sector Perform Rating | MT |
Apr. 02 | Bernstein starts AstraZeneca at 'outperform' | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.51 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.81 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.95% | 6.04B | C | ||
+12.14% | 45.6B | A- | ||
+5.25% | 39.03B | B | ||
+4.75% | 6.99B | C+ | ||
-7.94% | 5.25B | B | ||
+29.24% | 1.59B | C+ | ||
+4.63% | 1.55B | D+ | ||
-12.73% | 1.17B | C | ||
+3.80% | 1.06B | - | ||
-5.74% | 991M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DPLM Stock
- Ratings Diploma PLC